en
Scientific article
Meta-analysis
English

Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years

Published inOsteoporosis international, vol. 21, no. 6, p. 1031-1036
Publication date2010
Abstract

SUMMARY: From two randomised controlled trials, it is shown that 3-month changes in biochemical markers of bone formation (bone-specific alkaline phosphatase and C-terminal propeptide of type I procollagen) were associated with 3-year bone mineral density (BMD) changes, but not fracture incidence in patients treated with strontium ranelate. INTRODUCTION: The purpose of this study was to assess if short-term change in biochemical markers of bone remodelling is associated with long-term BMD change and fracture incidence observed during treatment with strontium ranelate. METHODS: From the SOTI and TROPOS trials, bone-specific alkaline phosphatase (BALP), C-terminal propeptide of type I procollagen (PICP), serum C-terminal telopeptides (S-CTX) and urine N-terminal telopeptides of type I collagen (U-NTX) were assessed at baseline and after 3 months. RESULTS: Two thousand three hundred seventy-three women were included in this study. Multiple regression analysis showed that 3-month changes in PICP and BALP but not s-CTX I nor s-NTX I were significantly (p < 0.001) associated with 3-year BMD changes at the lumbar spine and the femoral neck. Changes in s-CTX I, PICP and BALP were significantly associated with change in total proximal femur BMD. Changes in biochemical markers explain less than 8% of the BMD changes. The 3-month changes in BALP, PICP s-CTX I and s-NTX I were not significantly associated with fracture incidence. CONCLUSIONS: Short-term changes in biochemical markers of bone formation are associated with future BMD changes in patients treated with strontium ranelate, suggesting a bone-forming activity of this treatment, but are not appropriate to monitor the efficacy of strontium ranelate at the individual level.

Keywords
  • Aged
  • Aged, 80 and over
  • Alkaline Phosphatase/blood
  • Biological Markers/blood
  • Bone Density/*drug effects/physiology
  • Bone Density Conservation Agents/pharmacology/*therapeutic use
  • Bone Remodeling/*drug effects/physiology
  • Female
  • Femur Neck/physiopathology
  • Follow-Up Studies
  • Humans
  • Lumbar Vertebrae/physiopathology
  • Middle Aged
  • Organometallic Compounds/pharmacology/*therapeutic use
  • Osteoporosis, Postmenopausal/complications/drug therapy/physiopathology
  • Osteoporotic Fractures/etiology/physiopathology/*prevention & control
  • Peptide Fragments/blood
  • Procollagen/blood
  • Randomized Controlled Trials as Topic
  • Spinal Fractures/etiology/physiopathology/prevention & control
  • Thiophenes/pharmacology/*therapeutic use
Research group
Citation (ISO format)
BRUYERE, O. et al. Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years. In: Osteoporosis international, 2010, vol. 21, n° 6, p. 1031–1036. doi: 10.1007/s00198-009-1078-8
Main files (1)
Article
accessLevelRestricted
Identifiers
ISSN of the journal0937-941X
505views
0downloads

Technical informations

Creation05/23/2012 8:44:31 AM
First validation05/23/2012 8:44:31 AM
Update time03/14/2023 5:32:02 PM
Status update03/14/2023 5:32:01 PM
Last indexation02/12/2024 8:09:37 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack